Key Highlights
- Shares rose 5.57% in pre-market trading to $58.00, extending gains to a fresh 52-week high
- Presented Phase 2 long-term extension data for sutacimig showing an approximately 84% reduction in treated bleed rates in a key dosing cohort
- FDA endorsed the clinical data package as sufficient to advance sutacimig to a Phase 3 pivotal trial in Glanzmann thrombasthenia
- Unveiled HMB-003, a new antifibrinolytic candidate targeting heavy menstrual bleeding
- 52-week range stands at $23.00 to $55.42, with a market Capitalization of $2.57 billion
Shares Extend Rally on Bullish Analyst Actions
Hemab Therapeutics (NASDAQ:COAG) shares rose 5.57% in pre-market trading to $58.00, extending a multi-week rally to fresh 52-week highs following a string of bullish analyst actions after the company's second quarter Earnings report and pipeline updates. Multiple research firms raised price targets and reiterated Buy ratings after Hemab presented strong Phase 2 long-term extension data for sutacimig in Glanzmann thrombasthenia at the ISTH 2026 Congress in Paris, showing an approximately 84% reduction in treated bleed rates in a key low-dose weekly cohort.
The company also disclosed encouraging early data for HMB-002 in Von Willebrand disease and unveiled a new candidate, HMB-003, for heavy menstrual bleeding, an indication affecting more than 23 million women in the United States. Despite a wider-than-expected second quarter net loss of $0.80 per share versus a $0.63 consensus estimate, investor enthusiasm around the company's de-risked pipeline outweighed the earnings miss, with heavy institutional positioning evident from multiple 13G filings this week.
What Hemab Therapeutics Does
Hemab Therapeutics is a Cambridge, Massachusetts based clinical-stage biotechnology company, with additional operations in Denmark, dedicated to reimagining the treatment of rare blood coagulation disorders. Its lead candidate, sutacimig, is a bispecific antibody being developed as a subcutaneous prophylactic therapy for Glanzmann thrombasthenia and Factor VII deficiency, while its second clinical asset, HMB-002, targets Von Willebrand disease. The company also maintains a pipeline of preclinical and discovery-stage programs addressing serious bleeding and thrombotic diseases.
FDA Endorsement Clears Path to Phase 3
The FDA has endorsed the company's clinical data package as sufficient to proceed to a Phase 3 pivotal trial for sutacimig in Glanzmann thrombasthenia at a dose of 0.2 milligrams per kilogram once weekly, with initiation planned for the second half of 2026. Ninety-two percent of trial participants who had bled during the run-in period experienced reductions in treated bleed rates on sutacimig, with adverse events predominantly mild to moderate. The company ended the second quarter with $457.5 million in cash, cash equivalents, and marketable securities, which it expects will fund operations into 2029, following net proceeds of $317.2 million from its initial public offering completed in May 2026.
The Bottom Line
Hemab's continued rally reflects strong conviction in the company's de-risked path toward a Phase 3 pivotal trial in Glanzmann thrombasthenia, reinforced by encouraging early data across its broader bleeding disorder pipeline and a well-funded Balance Sheet extending into 2029. With Phase 3 initiation planned for the second half of 2026 and additional data expected from its Von Willebrand disease and antifibrinolytic programs in the coming year, the pace of clinical execution across multiple programs will likely remain the key driver of investor sentiment.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...